ADMA Biologics (ADMA) 10-K 9 Mar 15 2014 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Dec. 31, 2014	Mar. 06, 2015	Jun. 30, 2014
Document And Entity Information
Entity Registrant Name	ADMA BIOLOGICS, INC.
Entity Central Index Key	1368514
Document Type	10-K
Document Period End Date	31-Dec-14
Amendment Flag	FALSE
Current Fiscal Year End Date	-19
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$29,869,144
Entity Common Stock, Shares Outstanding		9,291,823
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2014

CONSOLIDATED_BALANCE_SHEETS

CONSOLIDATED BALANCE SHEETS (USD $)	Dec. 31, 2014	Dec. 31, 2013
Current Assets:
Cash and cash equivalents	$17,199,030	$26,149,477
Short-Term Investments	4,652,675	2,935,184
Accounts Receivable	383,961	0
Inventories	1,708,763	1,669,058
Prepaid Expenses	143,586	298,730
Total Current Assets	24,088,015	31,052,449
Property and Equipment at cost, Net	2,840,698	765,299
Other Assets:
Deferred Financing Costs	271,621	149,618
Deposits	27,163	12,577
Total Other Assets	298,784	162,195
TOTAL ASSETS	27,227,497	31,979,943
Current Liabilities:
Accounts Payable	1,779,197	2,709,489
Accrued expenses	2,223,639	823,550
Accrued Interest	105,664	36,597
Current Portion of Deferred Revenue	75,556	75,556
Current Portion of Leasehold Improvement Loan	13,841	12,654
Total Current Liabilities	4,197,897	3,657,846
Notes Payable, Net of Debt Discount	14,772,266	4,865,228
Warrant Liability	476,760	0
End of Term Liability, Notes Payable	132,500	132,500
Deferred Revenue	1,504,815	1,580,370
Deferred Rent Liability	83,214	105,404
Leasehold Improvement Loan	51,395	65,236
TOTAL LIABILITIES	21,218,847	10,406,584
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS' EQUITY
Common Stock $0.0001 par value 75,000,000 shares authorized, and 9,291,823 shares issued and outstanding	929	929
Additional paid-in capital	75,457,458	74,209,004
Accumulated Deficit	-69,449,737	-52,636,574
TOTAL STOCKHOLDERS' EQUITY	6,008,650	21,573,359
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$27,227,497	$31,979,943

CONSOLIDATED_BALANCE_SHEETS_Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Stockholders Equity
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	75,000,000	75,000,000
Common stock, issued	9,291,823	9,291,823
Common stock, outstanding	9,291,823	9,291,823

CONSOLIDATED_STATEMENTS_OF_OPE

CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
REVENUES:
Product revenue	$5,839,989	$3,023,503
License revenue	75,556	44,074
Total Revenues	5,915,545	3,067,577
OPERATING EXPENSES:
Cost of product revenue	3,742,367	2,023,441
Research and development	9,517,014	9,303,077
Plasma center	3,850,828	2,418,156
General and administrative	4,823,869	4,365,334
TOTAL OPERATING EXPENSES	21,934,078	18,110,008
LOSS FROM OPERATIONS	-16,018,533	-15,042,431
OTHER INCOME (EXPENSE):
Interest income	14,217	7,623
Interest expense	-1,286,215	-618,225
Change in fair value of warrant liability	-74,356	43,290
Other income	0	82,497
TOTAL OTHER INCOME (EXPENSE)	-1,346,354	-484,815
LOSS BEFORE INCOME TAXES	-17,364,887	-15,527,246
State income tax benefit	551,724	0
NET LOSS	($16,813,163)	($15,527,246)
NET LOSS PER COMMON SHARE, Basic and Diluted	($1.81)	($2.38)
WEIGHTED AVERAGE SHARES OUTSTANDING, Basic and Diluted	9,291,823	6,531,029

CONSOLIDATED_STATEMENTS_OF_CHA

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (USD $)	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Total
Beginning Balance, Amount at Dec. 31, 2012	$587	$46,532,487	($37,109,328)	$9,423,746
Beginning Balance, Shares at Dec. 31, 2012	5,871,002
Proceeds received from Initial Public Offering, net of equity issuance costs, Amount	342	26,602,167		26,602,509
Proceeds received from Initial Public Offering, net of equity issuance costs, Shares	3,420,821
Stock-based compensation		888,295		888,295
Elimination of warrant liability		186,055		186,055
Net loss			-15,527,246	-15,527,246
Ending Balance, Amount at Dec. 31, 2013	929	74,209,004	-52,636,574	21,573,359
Ending Balance, Shares at Dec. 31, 2013	9,291,823
Stock-based compensation		1,248,454		1,248,454
Elimination of warrant liability				0
Net loss			-16,813,163	-16,813,163
Ending Balance, Amount at Dec. 31, 2014	$929	$75,457,458	($69,449,737)	$6,008,650
Ending Balance, Shares at Dec. 31, 2014	9,291,823

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
CASH FLOWS FROM OPERATING ACTIVITIES:
Net Loss	($16,813,163)	($15,527,246)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	247,852	210,633
Stock-based compensation	1,248,454	888,295
Warrant liability	74,356	-43,290
Amortization of debt discount	133,197	91,704
Amortization of deferred financing costs	125,777	99,238
Payment-in-kind interest	176,245	0
Amortization of license revenue	-75,556	-44,074
Changes in operating assets and liabilities:
Accounts receivable	-383,961	39,112
Inventories	-39,704	-403,465
Prepaid Expenses	155,144	-190,969
Other assets	-14,586	593,051
Accounts payable	-937,779	1,608,980
Accrued expenses	1,351,937	76,471
Accrued interest	69,067	36,597
Deferred revenue	0	1,700,000
Deferred rent liability	-22,190	-22,191
Net cash used in operating activities	-14,704,910	-10,887,154
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of short-term investments	-1,717,492	-2,935,184
Purchase of property and equipment	-2,323,251	-196,635
Net cash used in investing activities	-4,040,743	-3,131,819
CASH FLOWS FROM FINANCING ACTIVITIES:
Net proceeds from issuance of common stock	0	27,030,820
Proceeds from Hercules note payable, net of fees	9,850,000	1,000,000
Debt issuance costs	-30,140	0
Equity issuance costs	-12,000	-386,473
Payments of leasehold improvement loan	-12,654	-11,569
Net cash provided by financing activities	9,795,206	27,632,778
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	-8,950,447	13,613,805
CASH AND CASH EQUIVALENTS - BEGINNING OF YEAR	26,149,477	12,535,672
CASH AND CASH EQUIVALENTS - END OF YEAR	17,199,030	26,149,477
SUPPLEMENTAL INFORMATION:
Cash paid for interest	785,527	382,736
Supplemental Disclosure of Noncash Financing Activities:
Reclassification of equity issuance costs to additional paid-in capital	0	428,311
Warrants issued in connection with note payable	402,404	0
Accrued equity issuance costs	55,640	41,838
End of term liability for Hercules note payable	0	26,500
Elimination of warrant liability	$0	$186,055

1_ORGANIZATION_AND_BUSINESS

1. ORGANIZATION AND BUSINESS	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
1. ORGANIZATION AND BUSINESS	ADMA Biologics, Inc. (“ADMA” or the “Company”) is a late stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of certain infectious diseases. The Company’s targeted patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease or who may be immune-suppressed for medical reasons. ADMA also operates its wholly owned subsidiary, ADMA BioCenters Georgia, Inc., (“ADMA BioCenters”), a source plasma collection business licensed by the United States Food and Drug Administration (“FDA”), certified by the German Health Authority (“GHA”) and the Korean Ministry of Food and Drug Safety (“MFDS”), which provides ADMA with a portion of its blood plasma for the manufacture of RI-002, ADMA’s lead product candidate, which is intended for the treatment of Primary Immune Deficiency Disease, (“PIDD”).
	The Company has experienced net losses and negative cash flows from operations since inception and expects these conditions to continue for the foreseeable future.  The Company has needed to raise capital from the sales of its equity and debt securities to sustain operations. In October 2013, the Company completed an Initial Public Offering (“IPO”) to raise gross proceeds of $29.1 million, and in February 2012, the Company completed a private placement to raise gross proceeds of $17.3 million (see Note 6), and during December 2012, February and December 2014, the Company borrowed a total of $15 million from Hercules Technology Growth Capital, Inc. (“Hercules”) (see Note 5).
	In October 2013, ADMA completed an initial public offering of its common stock at a price per share of $8.50, raising gross proceeds of $29.1 million. As of December 31, 2014, the Company had $17.2 million in cash and cash equivalents, $4.7 million in short-term investments and $0.4 million in accounts receivable.  Based upon the Company’s projected revenue and expenditures for 2015, management currently believes that its cash and cash equivalents and short-term investments as of December 31, 2014, are anticipated to be sufficient to fund ADMA’s operations into the first half of 2016.  Because the Company does not anticipate receiving FDA approval for RI-002 until, at the earliest, the first half of 2016, if at all, and would therefore not expect to generate revenue from the commercialization of RI-002 until after that date.  If the Company’s assumptions underlying its estimated expenses and revenues prove to be wrong, it may have to raise additional capital sooner than anticipated.  Due to numerous risks and uncertainties associated with the research and development and potential future commercialization of its product candidate, the Company is unable to estimate with certainty the amounts of increased capital outlays and operating expenditures associated with its anticipated clinical trials, development and commercialization activities.  The Company’s current estimates may be subject to change as circumstances regarding its business requirements develop.  The Company may decide to raise capital through public or private equity offerings, debt financings or corporate collaboration and licensing arrangements.  The Company does not have any existing commitments for future external funding.  The Company may seek to sell additional equity or debt securities or obtain an additional bank credit facility.  The sale of additional equity or debt securities, if convertible, could result in dilution to the Company’s stockholders.  The incurrence of additional indebtedness would result in increased fixed obligations and could also result in covenants that would restrict the Company’s operations or other financing alternatives.  Additional equity or debt financing, grants, or corporate collaboration and potential licensing arrangements may not be available on acceptable terms, if at all.  If adequate funds are not available, the Company may be required to delay, reduce the scope of or eliminate the Company’s research and development programs, reduce the Company’s planned clinical trials and delay or abandon potential commercialization efforts of the Company’s lead product candidate.  The Company’s ability to continue as a going concern will be dependent on its ability to raise additional capital when needed, to fund its research and development and commercial programs and to meet its obligations on a timely basis.
	ADMA’s long term liquidity will be dependent upon on its ability to raise additional capital, to fund its research and development and commercial programs and meet its obligations on a timely basis.  If ADMA is unable to successfully raise sufficient additional capital, it will likely not have sufficient cash flow and liquidity to fund its business operations, forcing ADMA to curtail activities and, ultimately, potentially cease operations. Even if ADMA is able to raise additional capital, such financings may only be available on unattractive terms, resulting in significant dilution of stockholders’ interests and, in such event, the value and potential future market price of its common stock may decline.
	There can be no assurance that the Company’s research and development will be successfully completed or that any product will be approved or commercially viable.  The Company is subject to risks common to companies in the biotechnology industry including, but not limited to, dependence on collaborative arrangements, development by the Company or its competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, and compliance with FDA and other governmental regulations and approval requirements.
	ADMA’s primary focus since 2004 has been conducting research and development of human plasma-derived products for the treatment of specific disease states.  The plasma collection center in Norcross, Georgia was established in 2008 as a complementary business operation.  The Norcross, Georgia facility received its FDA license in August 2011.  Under FDA license, ADMA BioCenters can collect normal source plasma and high-titer Respiratory Syncytial Virus, (“RSV”) plasma.  The Company sells a portion of the collected normal source plasma to buyers in the open “spot” market.  The Company also plans to use the high-titer RSV plasma collected by ADMA BioCenters in the manufacturing of RI-002.

2_SUMMARY_OF_SIGNIFICANT_ACCOU

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	The following comprises the Company’s significant accounting policies:
	Basis of presentation
	The accompanying consolidated financial statements include the accounts of ADMA Biologics, Inc. and its wholly-owned subsidiaries.  All significant intercompany transactions and balances have been eliminated in consolidation.
	Cash and cash equivalents
	The Company considers all highly-liquid instruments purchased with a maturity of three months or less to be cash equivalents.  The Company purchases certificates of deposits with maturity schedules of three, six, nine and twelve months.  Instruments with original maturities greater than three months but less than twelve months are included in short-term investments.
	The Company regularly maintains cash and short-term investments at third-party financial institutions in excess of the Federal Deposit Insurance Corporation, or FDIC, insurance limit. While the Company monitors the daily cash balances in the operating accounts and adjusts the balances as appropriate, these balances could be impacted, and there could be a material adverse effect on our business, if one or more of the financial institutions with which the Company has deposits fails or is subject to other adverse conditions in the financial or credit markets. To date, the Company has not experienced a loss or lack of access to its invested cash or cash equivalents; however, the Company cannot provide assurance that access to its invested cash and cash equivalents will not be impacted by adverse conditions in the financial and credit markets.
	Inventories
	Plasma inventories (both plasma intended for resale and plasma intended for internal use in our research and development activities) are carried at the lower of cost or market value determined on the first-in, first-out method.    Once the research and development plasma is processed to a finished good it is then expensed to research and development for its clinical study programs.  Finished good RSV and normal source plasma is also capitalized to inventory for its potential commercialization and would subsequently be sold upon the Company receiving approval from the FDA.  Inventory at December 31, 2014 and 2013 consists of finished good RSV and normal source plasma.  Inventory also includes plasma collected at the Company’s FDA licensed plasma collection center.
	Revenue recognition
	Revenue from the sale of human plasma collected at the Company’s FDA licensed plasma collection center and plasma-derived medicinal products is recognized at the time of transfer of title and risk of loss to the customer, which occurs at the time of shipment.  Revenue is recognized at the time of delivery if the Company retains the risk of loss during shipment.  The Company’s revenues are substantially attributed to one customer.  Revenue from license fees and research and development services rendered are recognized as revenue when the performance obligations under the terms of the license agreement have been completed.  Deferred revenue of $1.7 million was recorded in 2013 as a result of certain research and development services to be provided in accordance with a license agreement and is recognized over the term of the license.  Deferred revenue is amortized into income for a period of approximately 20 years, the term of the license agreement.
	Concentration of significant customers and accounts receivable
	As of and for the years ended December 31, 2014 and 2013, the Company’s trade receivable balance and revenues were substantially attributable to one customer.
	Research and development costs
	The Company expenses all research and development costs as incurred including plasma and equipment for which there is no alternative future use.  Such expenses include licensing fees and costs associated with planning and conducting clinical trials.
	Use of estimates
	The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Actual results could differ from those estimates.  Significant estimates include valuation of inventory, assumptions used in the fair value of stock-based compensation and warrant valuation, and the allowance for the valuation of future tax benefits.
	Concentration of credit risk
	Financial instruments which potentially subject the Company to concentrations of credit risk consist of cash and cash equivalents and short-term investments.
	Property and equipment
	Fixed assets are stated at cost less accumulated depreciation.  Depreciation is calculated using the straight-line method over the asset’s estimated useful life, which is five to ten years.  Leasehold improvements are amortized over the lesser of the lease term or their estimated useful lives.
	Income taxes
	The Company recognizes deferred tax liabilities and assets for the expected future tax consequences of events that have been included in the financial statements or tax returns.  Under this method, deferred tax liabilities and assets are determined on the basis of the difference between the tax basis of assets and liabilities and their respective financial reporting amounts (“temporary differences”) at enacted tax rates in effect for the years in which the temporary differences are expected to reverse.  The Company records a valuation allowance on its deferred income tax assets if it is more likely than not that these deferred income tax assets will not be realized.
	The Company has no unrecognized tax benefits at December 31, 2014 and 2013.  The Company’s U.S. Federal and state income tax returns prior to fiscal year 2011 are closed and management continually evaluates expiring statutes of limitations, audits, proposed settlements, changes in tax law and new authoritative rulings.
	The Company will recognize interest and penalties associated with tax matters as income tax expense.
	Earnings (Loss) Per Share
	Basic net loss per share is computed by dividing net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding during the period.  Diluted net loss per share is calculated by dividing net loss applicable to common stockholders as adjusted for the effect of dilutive securities, if any, by the weighted average number of common stock and dilutive common stock outstanding during the period.  No potentially dilutive securities are included in the computation of any diluted per share amounts as the Company reported a net loss for all periods presented.  Potentially dilutive securities that would be issued upon the exercise of outstanding warrants and stock options were 1.3 million at December 31, 2014 and 1.0 million at December 31, 2013.
	Stock-based compensation
	The Company follows recognized accounting guidance which requires all stock-based payments, including grants of stock options, to be recognized in the statement of operations as compensation expense, based on their fair values on the grant date.  The estimated fair value of options granted under the Company’s 2007 Employee Stock Option Plan (the “Plan”) are recognized as compensation expense over the option-service period.
	On June 19, 2014, at the Annual Meeting of Stockholders (the “Annual Meeting”), the stockholders approved the 2014 Omnibus Incentive Compensation Plan (the “2014 Plan”), which was approved by the Board of Directors of ADMA (“the Board”) on February 21, 2014.  Grants of incentive stock options to purchase an aggregate of 167,932 shares of the Company's common stock under the 2014 Plan to three executive officers were approved by the Board on February 21, 2014, and conditioned upon the approval of the 2014 Plan.  These stock options are comprised of 99,309 shares for the Company’s President and Chief Executive Officer, Adam S. Grossman; 39,032 shares for the Company’s Chief Financial Officer, Brian Lenz; and 29,591 shares for the Company's Chief Scientific and Medical Officer, James Mond, M.D., Ph.D.  The stock options vest over a period of four years and are exercisable at a price per share of $8.50, the closing price of the Company’s common stock on the OTC Bulletin Board on February 21, 2014.  Grants of non-qualified stock options to purchase 9,000 shares of the Company's common stock under the 2014 Plan, to each of the Company’s six non-employee directors, were approved by the Board on February 21, 2014, and were also conditioned upon the approval of the 2014 Plan at the 2014 Annual Meeting of Stockholders.  The stock options will vest over a period of 24 months and terminate 12 months following separation and are exercisable at a price per share of $8.50, the closing price of the Company’s common stock on the OTC Bulletin Board on February 21, 2014. The maximum number of shares reserved for grant under the 2014 Plan is: (a) 800,000 shares; plus (b) an annual increase as of the first day of the Company’s fiscal year, beginning in 2015 and occurring each year thereafter through 2020, equal to the least of (i) 200,000 shares, (ii) 1% of the outstanding shares of common stock as of the end of the Company’s immediately preceding fiscal year, and (iii) any lesser number of shares determined by the Board; provided, however, that the aggregate number of shares available for issuance pursuant to such increases shall not exceed a total of 800,000 shares.  During the years ended December 31, 2014 and 2013, stock options to purchase 221,932 and 84,134 shares of common stock, respectively, were issued to employees and non-employee directors.
	During the years ended December 31, 2014 and 2013, the Company recorded stock-based compensation expense to employees of $1,248,454 and $888,295, respectively.  The fair value of employee options granted was determined on the date of grant using the Black-Scholes model.  The Black-Scholes option valuation model was developed for use in estimating the fair value of publicly traded options, which have no vesting restrictions and are fully transferable.  In addition, option valuation models require the input of highly subjective assumptions including the expected stock price volatility.  The Company’s employee stock options have characteristics significantly different from those of traded options, and changes in the subjective input assumptions can materially affect the fair value estimate.  Because the Company has had very little historical experience with the Company’s stock options, small similar publicly traded companies were used for comparison and expectations as to assumptions required for fair value computation using the Black-Scholes methodology.  Guidance for stock-based compensation requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.  The Company currently estimates there will be no forfeitures of options.  Due to the Company’s limited history and as permitted under recognized guidance, the Company uses the simplified method, to determine the expected life of the option grants, which is the average between vesting terms and contractual terms.
	The Company records compensation expense associated with stock options and other forms of equity compensation using the Black-Scholes option-pricing model and the following assumptions:
		Year Ended	Year Ended
		31-Dec-14	31-Dec-13
	Expected term	6.3 years	6.3 years
	Volatility	60%	63%
	Dividend yield	0	0
	Risk-free interest rate	2.19%	1.24-2.25%
	Fair value of financial instruments
	The carrying amounts of certain of the Company’s financial instruments, including cash and cash equivalents, short-term investments, accounts payable, and notes payable are shown at cost which approximates fair value due to the short-term nature of these instruments.

3_PROPERTY_AND_EQUIPMENT

3. PROPERTY AND EQUIPMENT	12 Months Ended
	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
3. PROPERTY AND EQUIPMENT	Property and equipment consist of the following at December 31,	2014			2013
	Lab and office equipment	$	1,236,553		$	674,885
	Computer software		188,277			184,077
	Leasehold improvements		2,699,736			942,353
			4,124,566			1,801,315
	Less: Accumulated depreciation and amortization		(1,283,868	)		(1,036,016	)
		$	2,840,698		$	765,299
	The Company recorded depreciation and amortization expense of $247,852 and $210,633 for the years ended December 31, 2014 and 2013, respectively.

4_LEASEHOLD_IMPROVEMENT_LOAN

4. LEASEHOLD IMPROVEMENT LOAN	12 Months Ended
	Dec. 31, 2014
Notes to Financial Statements
4. LEASEHOLD IMPROVEMENT LOAN	In connection with the lease of commercial real estate by the Company’s wholly-owned subsidiary for the operation of the plasma collection center, the Company borrowed $125,980 from the lessor to pay for leasehold improvement costs in excess of the allowance provided for in the lease agreement.  The loan bears interest at 9% and is payable in 120 monthly installments of $1,596 maturing January 2019.  Principal maturities under the loan are as follows:
	2015	$	13,841
	2016		15,139
	2017		16,559
	2018		18,113
	2019		1,584
		$	65,236

5_DEBT

5. DEBT	12 Months Ended
	Dec. 31, 2014
Debt Disclosure [Abstract]
5. DEBT	Hercules Debt Agreement
	On December 21, 2012, the Company and its subsidiaries entered into a Loan and Security Agreement, or the Loan Agreement, with Hercules.  Under the Loan Agreement, the Company borrowed $5.0 million, consisting of $4.0 million on the closing date, and an additional $1.0 million upon enrolling its first patient in its pivotal (Phase III) clinical study of its lead product candidate RI-002.
	On February 24, 2014, the Company entered into the First Amendment to the Loan Agreement, or Loan Amendment, under which the Company has borrowed $15.0 million in the aggregate as of December 31, 2014, comprised of $10.0 million on the closing date, ($5.0 million of which was used to refinance existing debt with Hercules) and an additional $5.0 million the Company accessed in December 2014 when the Company successfully announced the clinical endpoints of its Phase III clinical study of RI-002 as a treatment for PIDD in a manner that supports a Biologics License Application, (“BLA”) filing. The loan bears interest at a rate per annum equal to the greater of (i) 8.75% and (ii) the sum of (a) 8.75% plus (b) the Prime Rate (as reported in The Wall Street Journal) minus (c) 5.75%. Payment-in-kind interest accrues on the outstanding principal balance of the loan compounded monthly at 1.95% per annum.  Such accrued and unpaid interest is added to the principal balance of the loan on the first day of each month beginning on the month after the closing.  The Company is obligated to begin to repay the principal over 18 months beginning October 1, 2015, unless accelerated as a result of certain events of default.  A backend fee equal to $132,500 is due the earliest of April 1, 2016, which is related to the original Loan Agreement, the prepayment date and the date that the secured obligations become due and payable.  In addition, a first amendment commitment fee and a facility fee in the amount of $15,000 and $135,000, respectively, were paid at closing.   In the event the Company elects to prepay the loan, the Company is obligated to pay a prepayment charge corresponding to a percentage of the principal amount of the loan, with such percentage being: 2.5% if prepayment occurs in the first year, 1.5% if prepayment occurs in the second year and 0.5% if prepayment occurs after the second year but prior to the final day of the term.  The loan matures no later than January 1, 2018.  The loan is secured by our assets, except for our intellectual property (which is subject to a negative pledge). Interest is due and payable on the 1st of every month and at the termination date, unless accelerated as a result of an event of default. The Loan Agreement contains customary representations, warranties and covenants, including limitations on incurring indebtedness, engaging in mergers or acquisitions and making investments, distributions or transfers.  The representations, warranties and covenants contained in the Loan Agreement were made only for purposes of such agreement and as of a specific date or specific dates, were solely for the benefit of the parties to such agreement, and may be subject to limitations agreed upon by the contracting parties, including being qualified by confidential disclosures exchanged between the parties in connection with the execution of the Loan Agreement. Events of default under the agreement include, but are not limited to: (i) insolvency, liquidation, bankruptcy or similar events; (ii) failure to pay any debts due under the Loan Agreement or other loan documents on a timely basis; (iii) failure to observe any covenant or secured obligation under the Loan Agreement or other loan documents, which failure, in most cases, is not cured within 10 days of written notice by lender; (iv) occurrence of any default under any other agreement between us and the lender, which is not cured within 10 days; (v) occurrence of an event that could reasonably be expected to have a material adverse effect;  (vi) material misrepresentations; (vii) occurrence of any default under any other agreement involving indebtedness in excess of $50,000 or the occurrence of a default under any agreement that could reasonably be expected to have a material adverse effect; and (viii) certain money judgments are entered against us or a certain portion of our assets are attached or seized. Remedies for events of default include acceleration of amounts owing under the Loan Agreement and taking immediate possession of, and selling, any collateral securing the loan.
	In connection with the original Loan Agreement, the Company issued to Hercules a warrant to purchase 31,750 shares of common stock with an exercise price of $7.56, and under the amended Loan Agreement, the Company issued to Hercules a warrant to purchase an additional 58,000 shares of its common stock, comprised of a warrant to purchase 23,200 shares of common stock issued in February 2014 and a warrant to purchase 34,800 shares of common stock issued in December 2014, each warrant issued upon the drawdown of each $5.0 million of additional debt, with an exercise price set at the lower of (i) $7.50 per share or (ii) the price per share of the next round of financing over the next twelve months, subject to customary anti-dilution adjustments.  The warrants expire after 10 years and have piggyback registration rights with respect to the shares of common stock underlying the warrant.  In addition, the Company has also granted Hercules the option to invest (until the loan maturity date) up to $1.0 million in future equity financings at the same terms as the other investors.  The Loan Agreement contains certain provisions that require the warrants issued to Hercules to be accounted for as a liability and to be “mark-to-market” each reporting period.  Changes in the valuation of this liability at the end of each reporting period will be included in its reported operating results, and may create volatility in its reported operating results. The fair value of the initial Loan Agreement warrant was calculated using a lattice-based option model in order to account for features in the warrant that could cause the exercise price to reset (“down round protection”) as a result of the next issuance of our common stock (the next round of equity financing). The Company recorded the fair value of the warrant to purchase 31,750 shares of common stock of $229,345 as warrant liability and as a debt discount to the carrying value of the loan.  The key assumptions used to value the warrants included the expected date of the next round of equity financing, volatility of 59% on our common stock based upon similar public companies’ volatilities for comparison, an expected dividend yield of 0.0%, a risk-free interest rate of 2.54% and a term of 10 years.  As of October 22, 2013, the closing date of the IPO, the Company recorded $186,055 as the fair value of this warrant, as additional paid-in capital.   As a result of the decrease in warrant liability, the Company recorded a $43,290 change in the fair value of warrant liability.  This warrant liability was adjusted from inception of the initial Loan Agreement to October 22, 2013, to fair value each reporting period using a lattice-based option model and the debt discount will be amortized to interest expense over the term of the loan using the effective interest method. Upon the completion of the IPO of common stock in October 2013, the down round warrant protection feature resulting in the warrant liability’s quarterly “mark-to-market” valuation terminated and, therefore, this liability was reclassified to additional paid-in capital during the fourth quarter of 2013. The fair value of the amended Loan Agreement warrant was calculated using a lattice-based option model in order to account for features in the warrant that could cause the exercise price to reset (“down round protection”) as a result of the next issuance of our common stock (the next round of equity financing). The Company initially recorded the fair value of the warrant of $219,588 as warrant liability and as a debt discount to the carrying value of the loan.  The key assumptions used to value the warrants included the expected date of the next round of equity financing, volatility of 59% on our common stock based upon similar public companies’ volatilities for comparison, an expected dividend yield of 0.0%, a risk-free interest rate of 2.53% and a term of 10 years.  As of December 31, 2014, the Company recorded $476,760 as the fair value of the warrant for the purchase of 58,000 shares of common stock. As a result of the increase in warrant liability, the Company recorded an expense of $74,356 from the change in the fair value of warrant liability.  This warrant liability was adjusted from the date of the Loan Agreement on February 24, 2014, to fair value each reporting period using a lattice-based option model and the debt discount will be amortized to interest expense over the term of the loan. The down round warrant protection feature resulting in the warrant liability’s quarterly “mark-to-market” valuation has terminated as of  the end of the one-year period following the amended Loan Closing on February 24, 2014.

6_STOCKHOLDERS_EQUITY

6. STOCKHOLDERS' EQUITY	12 Months Ended
	Dec. 31, 2014
Equity [Abstract]
6. STOCKHOLDERS' EQUITY	Hercules Debt Financing Warrant Issuance
	In connection with the original Loan Agreement, the Company issued to Hercules a warrant to purchase 31,750 shares of common stock with an exercise price of $7.56, subject to customary anti-dilution adjustments.  In connection with the Loan Amendment, the Company issued to Hercules a warrant to purchase 58,000 shares of common stock of the Company with an exercise price set at the lower of (i) $7.50 per share or (ii) the price per share of the next round of financing from the expiration of the exercise price adjustment, subject to customary anti-dilution adjustments.  The warrant expires after 10 years and has piggyback registration rights with respect to the shares of common stock underlying the warrant.  The down round warrant protection feature resulting in the warrant liability’s quarterly “mark-to-market” valuation has terminated as of  the end of the one-year period following the amended Loan Closing on February 24, 2014.  See Note 5 Debt.
	2012 Merger and Financing
	On February 13, 2012, in connection with, and immediately prior to the closing of the Merger (as defined below), the Company completed a private placement (the “2012 Financing”) of 2,321,723 shares of the Company’s common stock at a price per share of $7.56 to accredited investors, for gross proceeds to the Company of $17,550,029 pursuant to a securities purchase agreement (the “Securities Purchase Agreement”). In lieu of repayment of senior secured promissory notes in the aggregate principal amount of $250,000 (plus $12,740 in accrued interest), the aggregate amount of unpaid principal and interest on the notes was invested by the holders of such notes in the 2012 Financing in exchange for shares of the Company’s common stock.  The net cash proceeds from the 2012 Financing, after the payment of all expenses related to the 2012 Financing and the Merger, approximated $15.3 million.
	The placement agent was paid a cash fee by the Company for its services.  As additional compensation, the Company issued the placement agent warrants (the “Placement Agent Warrants”) to purchase 111,587 shares of common stock of the Company.  The Placement Agent Warrants, which were exchanged for warrants of the Company in the Merger, are exercisable at $7.56 per share of Common Stock at any time beginning on August 11, 2012 and ending on February 12, 2017.  The Company also agreed to reimburse the Placement Agent for up to $100,000 of expenses it incurred in connection with the 2012 Financing and to indemnify it against certain liabilities in connection with the 2012 Financing.
	On February 13, 2012, the Company entered into a merger agreement whereby forming ADMA Acquisition Sub, Inc., a Delaware corporation (“Acquisition Sub”) (“Merger”). Upon closing of the Merger, Acquisition Sub was merged with and into the Company, and the Company, as the surviving corporation in the Merger, became a wholly-owned subsidiary of the Company and the corporate name was changed to ADMA Biologics, Inc.
	For accounting purposes, the Merger was accounted for as a reverse acquisition, with the Company as the accounting acquiror (legal acquiree) and parentco as the accounting acquiree (legal acquiror), effectively a recapitalization of the Company.
	Following the Merger, the Company was authorized by its certificate of incorporation to issue an aggregate of 85,000,000 shares of capital stock, of which 75,000,000 are shares of common stock and 10,000,000 are shares of preferred stock, each with a par value of $0.0001 per share.
	During October and November the Company completed its IPO and overallotment of common stock by issuing 3,420,821 shares of its common stock, priced at $8.50 per share.  Aggregate net proceeds to ADMA, after deducting underwriting discounts and commissions and expenses was $26.6 million.

7_RELATED_PARTY_TRANSACTIONS

7. RELATED PARTY TRANSACTIONS	12 Months Ended
	Dec. 31, 2014
Related Party Transactions [Abstract]
7. RELATED PARTY TRANSACTIONS	The Company leases an office building and equipment from an entity owned by related parties on a month-to-month basis.  Rent expense amounted to $96,448 for each of the years ended December 31, 2014 and 2013, respectively.  The Company maintains deposits and other accounts at a bank which is less than 5%-owned by related parties and where a stockholder is a member of the Board of Directors of the bank.

8_COMMITMENTS_AND_CONTINGENCIE

8. COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
8. COMMITMENTS AND CONTINGENCIES	Lease commitments
	The Company has entered into leases for it ADMA BioCenters’ facilities located in Norcross, Georgia and in Marietta, Georgia.  The Norcross, Georgia lease expires on September 30, 2023, and the Marietta, Georgia lease expires on January 31, 2024.  Total rent expense for its New Jersey and Georgia facilities during the years ended 2014 and 2013 was approximately, $414,000 and $253,000, respectively.
	Future minimum lease payments for both leases, for each of the five years ending December 31 and thereafter are as follows:
	2015	$	330,176
	2016		348,383
	2017		353,059
	2018		356,774
	2019		369,198
	Thereafter		1,465,720
		$	3,223,310
	Vendor and Licensor Commitments
	On December 31, 2012, the Company entered into a Manufacturing, Supply and License Agreement with Biotest, which replaces a prior agreement that expired on December 31, 2012.  Under the agreement, the Company agreed to purchase exclusively from Biotest its worldwide requirements of RSV immune globulin manufactured from human plasma containing RSV antibodies.  The term of the agreement is for a period of ten years from January 1, 2013, renewable for two additional five-year periods at the agreement of both parties. The Company is obligated under this agreement to purchase a minimum of at least one lot of product during each calendar year after the finished product is approved by the FDA.  This number is subject to increase at the Company’s option.  As consideration for Biotest’s obligations under the agreement, the Company is obligated to pay a dollar amount per lot of RSV immune globulin manufactured from human plasma containing RSV antibodies, as well as a percentage royalty on the sales thereof and of RI-002, up to a specified cumulative maximum.  The agreement may be terminated by either party (a) by reason of a material breach if the breaching party fails to remedy the breach within 120 days after receiving notice of the breach from the other party, (b) upon bankruptcy, insolvency, dissolution, or winding up of the other party, or (c) if the other party is unable to fulfill its obligations under the agreement for 120 consecutive days or more as a result of (a) or (b) above.
	In a separate license agreement effective December 31, 2012, the Company granted Biotest an exclusive license to market and sell RSV antibody-enriched Immune Globulin Intravenous (“IGIV”) in Europe and in selected countries in North Africa and the Middle East, collectively referred to as the Territory, to have access to the Company’s testing services for testing of Biotest’s plasma samples using the Company’s proprietary RSV assay, and to reference (but not access) the Company’s proprietary information for the purpose of Biotest seeking regulatory approval for the RSV antibody-enriched IGIV in the Territory.  As consideration for the license, Biotest agreed to provide the Company with certain services at no charge and also compensate us with cash payments upon the completion of certain milestones.  Such services have been accounted for as deferred revenue which were recorded in 2013 as a result of certain research and development services as provided for in accordance with a license agreement.  Deferred revenue is recognized over the term of the license and is amortized into income for a period of approximately 20 years, the term of the license agreement. Biotest is also obligated to pay the Company an adjustable royalty based on a percentage of revenues from the sale of RSV antibody-enriched IGIV in the Territory for 20 years from the date of first commercial sale. Additionally, Biotest has agreed to grant the Company an exclusive license for marketing and sales in the United States and Canada for Biotest’s Varicella Zoster Immune Globulin (“VZIG”), the terms of which the Company expects to finalize during 2015.  As such, the Company expects to account for the value of this license as a charge to operations once the terms of the in-license agreement are finalized.
	Pursuant to the terms of a Plasma Purchase Agreement with Biotest, the Company has agreed to purchase from Biotest an annual minimum volume of source plasma containing antibodies to RSV to be used in the manufacture of RI-002.  This volume will increase at the earlier of our receipt of a BLA from the FDA, or March 31, 2016.  The Company must purchase a to-be-determined and agreed upon annual minimum volume from Biotest but may also collect high-titer RSV plasma from up to five wholly-owned ADMA BioCenters.  Unless terminated earlier, the agreement expires in November 2021, after which it may be renewed for two additional five-year periods if agreed to by the parties.  Either party may terminate the agreement if the other party fails to remedy any material default in the performance of any material condition or obligation under the agreement following notice.  Either party may also terminate the agreement, after providing written notice, if a proceeding under any bankruptcy, reorganization, arrangement of debts, insolvency or receivership law is filed by or against the other party, and is not dismissed or stayed, or a receiver or trustee is appointed for all or a substantial portion of the assets of the other party, or the other party makes an assignment for the benefit of its creditors or becomes insolvent.  The Company may also terminate the agreement upon written notice if the clinical development of our product candidate is halted or terminated, whether by the FDA, a Data Safety Monitoring Board, or any other regulatory authority.  Upon termination of the agreement, the Company must pay for any source plasma already delivered to the Company and for any source plasma collected under the terms of the agreement.
	Employment contracts
	The Company has entered into employment agreements with its executive management team consisting of its President and Chief Executive Officer, Chief Medical and Scientific Officer and Chief Financial Officer.  In accordance with the employment agreements, the total financial obligation the Company has with the named executives approximates $1.5 million.
	General legal matters
	The Company is subject to certain legal proceedings and claims arising in connection with the normal course of its business. In the opinion of management, there are currently no claims that would have a material adverse effect on its consolidated financial position, results of operations or cash flows.
	Other commitments
	In the normal course of business, the Company enters into contracts that contain a variety of indemnifications with its employees, licensors, suppliers and service providers. Further, the Company indemnifies its directors and officers who are, or were, serving at the Company’s request in such capacities. The Company’s maximum exposure under these arrangements is unknown as of December 31, 2014. The Company does not anticipate recognizing any significant losses relating to these arrangements.

9_STOCK_OPTIONS

9. STOCK OPTIONS	12 Months Ended
	Dec. 31, 2014
Equity [Abstract]
9. STOCK OPTIONS	On July 16, 2007 (the “Effective Date”), the Company’s Board and stockholders adopted the 2007 Employee Stock Options Plan (the “Plan”).  On July 17, 2012, the Company’s Board and stockholders amended the Plan to increase the aggregate number of options available for grant to 903,224.  On February 21, 2014, the Board of the Company approved, subject to stockholder approval at the Company's 2014 Annual Meeting of the 2014 Omnibus Incentive Compensation Plan of the Company (the “Prospective Plan”), incentive stock options to purchase an aggregate of 167,932 shares of the Company's common stock under the Prospective  Plan, which was subject to stockholder approval at the Annual Meeting, to three of its executive officers, of which options to purchase 99,309 shares were approved by the Board for the Company’s President and Chief Executive Officer, Adam S. Grossman; options to purchase 39,032 shares were approved by the Board for the Company’s Chief Financial Officer, Brian Lenz; and options to purchase 29,591 shares were approved by the Board for the Company's Chief Scientific and Medical Officer, James Mond, M.D., Ph.D.  The options will vest over a period of four years and are exercisable at a price per share of $8.50, the closing price of the Company’s common stock on the OTC Bulletin Board on February 21, 2014.
	The Board also approved, subject to stockholder approval at the Annual Meeting under the Prospective Plan, nonqualified stock options to purchase an aggregate of 54,000 shares of the Company’s common stock to its Board.  Such options will vest over a period of two years and are exercisable at a price per share of $8.50, the closing price of the Company’s common stock on the OTC Bulletin Board on February 21, 2014.  Additionally, the Board also, approved subject to stockholder approval at the Annual meeting under the Prospective Plan, 800,000 shares of common stock plus an annual increase to be added as of the first day of the Company’s fiscal year, beginning in 2015 and occurring each year thereafter through 2020, equal to the lower of 200,000, or 1% of the outstanding shares of common stock as of the end of the Company’s immediately preceding fiscal year and  any lesser number of shares determined by the Board, provided that the aggregate number of shares available for issuance pursuant to such increases shall not exceed a total of 800,000 shares reserved for issuance under the terms of  the  Prospective Plan.
	The Plan provides for the Board or a Committee of the Board (the “Committee”) to grant awards to optionees and to determine the exercise price, vesting term, expiration date and all other terms and conditions of the awards, including acceleration of the vesting of an award at any time.  All options granted under the Plan are intended to be incentive stock options (“ISOs”), unless specified by the Committee to be non-qualified options (“NQOs”) as defined by the Internal Revenue Code.  ISOs and NQOs may be granted to employees, consultants or Board members at an option price not less than the fair market value of the common stock subject to the Stock Option Agreement.  The following table summarizes information about stock options outstanding as of December 31, 2014 and 2013:
		Year Ended				Year Ended
		31-Dec-14				December 31, 2013
				Weighted					Weighted
				Average					Average
				Exercise					Exercise
		Shares		Price		Shares			Price
	Outstanding at beginning of year		826,995	$	6.9		749,211		$	6.86
	Forfeited		-		-		(6,350	)	$	7.56
	Granted		221,932	$	8.5		84,134		$	7.56
	Outstanding at end of year and expected to vest		1,048,927	$	7.24		826,995		$	6.9
	Options exercisable		635,763	$	6.81		391,822		$	6.23
	Weighted average fair value of options
	granted during the year			$	5.06				$	4.35
	The weighted average remaining contractual term of stock options outstanding and expected to vest at December 31, 2014 is 7.3 years.  The weighted average remaining contractual term of stock options exercisable at December 31, 2014 is 6.7 years.
	Stock-based compensation expense for the years ended December 31, 2014 and 2013 was:
		2014		2013
	Research and development	$	541,140	$	227,085
	Plasma centers		56,900		-
	General and administrative		650,414		661,210
	Total stock-based compensation expense	$	1,248,454	$	888,295
	As of December 31, 2014, the total unrecognized compensation expense related to unvested options totaled $2,158,560. The weighted-average vesting period over which the total compensation expense will be recorded related to unvested options at December 31, 2014 was approximately 2.1 years.  As of December 31, 2014, the Company had 654,297 options available for future grant under the Plan.
	The aggregate intrinsic value is calculated as the difference between (i) the closing price of the common stock at December 31, 2014 and (ii) the exercise price of the underlying awards, multiplied by the number of options that had an exercise price less than the closing price on the last trading day. Our outstanding and exercisable options had an intrinsic value of $4,121,481 and $2,771,874 as of December 31, 2014, respectively.

10_INCOME_TAXES

10. INCOME TAXES	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
10. INCOME TAXES	A reconciliation of income taxes at the U.S. Federal statutory rate to the benefit for income taxes is as follows:
		Year Ended December 31,
		2014			2013
	Benefit at US Federal statutory rate	$	(5,904,062	)	$	(5,279,264	)
	State taxes - deferred		879,793			(901,800	)
	Increase in valuation allowance		5,147,244			6,850,118
	Research and development credits		(551,863	)		(599,003	)
	Sale of state net operating loss		(551,724	)		-
	Other		428,888			(70,051	)
	Benefit for income taxes	$	(551,724	)	$	-
	A summary of our deferred tax assets is as follows:
		Year Ended December 31,
		2014			2013
	Federal and state net operating loss carryforwards	$	21,004,587		$	16,791,893
	Federal and state research credits		3,649,268			2,846,245
	Accrued expenses and other		884,472			752,945
	Total gross deferred tax assets		25,538,327			20,391,083
	Less: valuation allowance for deferred tax assets		(25,538,327	)		(20,391,083	)
	Net deferred tax assets	$	-		$	-
	As of December 31, 2014, the Company had Federal and state net operating loss carryforwards of approximately $58.9 million and $31.9 million, respectively.  The Company also had Federal and state research and development tax credit carryforwards of approximately $3.0 million and $0.6 million, respectively.  The net operating loss carryforwards and tax credits will expire at various dates beginning in 2027 if not utilized.
	The Company received $551,724 in December 2014 from the sale of net operating loss and research and development credit carryforwards under the New Jersey Economic Development Authority Technology Business Tax Certificate Transfer Program.  These amounts are recorded on the financial statements as income tax benefits in the year they are received.

11_SEGMENTS

11. SEGMENTS	12 Months Ended
	Dec. 31, 2014
Segment Reporting [Abstract]
11. SEGMENTS	The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics.  The Company also operates an FDA-licensed source plasma collection facility located in Norcross, Georgia and a facility in Marietta, Georgia which is pending regulatory licensure and certification.  The Company defines its segments as those business units whose operating results are regularly reviewed by the chief operating decision maker (“CODM”) to analyze performance and allocate resources.  The Company’s CODM, is its President and Chief Executive Officer.
	The plasma collection center segment includes the Company’s operation in Georgia.  The research and development segment includes the Company’s plasma development operations in New Jersey.
	Summarized financial information concerning reportable segments is shown in the following table:
	Year Ended December 31,	Plasma Collection			Research and
	2014	Center			Development			Corporate			Consolidated
	Revenues	$	5,839,989		$	-		$	75,556		$	5,915,545
	Cost of product revenue		3,742,367			-			-			3,742,367
	Gross profit		2,097,622			-			75,556			2,173,178
	Loss from operations		(1,753,206	)		(9,517,014	)		(4,748,313	)		(16,018,533	)
	Other income (expense)		262			-			(1,346,616	)		(1,346,354	)
	Loss before income taxes		(1,752,944	)		(9,517,014	)		(6,094,929	)		(17,364,887	)
	Property and equipment, net		2,697,390			-			143,308			2,840,698
	Depreciation and
	amortization expense		198,244			2,729			46,879			247,852
	Year Ended December 31,	Plasma Collection			Research and
	2013	Center			Development			Corporate			Consolidated
	Revenues	$	3,023,503		$	-		$	44,074		$	3,067,577
	Cost of product revenue		2,023,441			-			-			2,023,441
	Gross profit		1,000,062			-			44,074			1,044,136
	Loss from operations		(1,418,094	)		(9,303,077	)		(4,321,260	)		(15,042,431	)
	Other expense		(7,582	)		-			(477,233	)		(484,815	)
	Loss before income taxes		(1,425,676	)		(9,303,077	)		(4,798,493	)		(15,527,246	)
	Property and equipment, net		587,032			2,729			175,538			765,299
	Depreciation and
	amortization expense		168,686			3,238			38,709			210,633
	The “Corporate” column includes general and administrative overhead expenses.  Property and equipment, net, included in the “Corporate” column above includes assets related to corporate and support functions.

12_SUBSEQUENT_EVENTS

12. SUBSEQUENT EVENTS	12 Months Ended
	Dec. 31, 2014
Subsequent Events [Abstract]
12. SUBSEQUENT EVENTS	Subsequent to the December 31, 2014, the Board approved a grant, in the aggregate, of 230,000 options to its executive, non-executive employees and members of the Board, along with a grant of 5,000 restricted shares of common stock to an employee.

2_SUMMARY_OF_SIGNIFICANT_ACCOU1

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Basis of presentation	The accompanying consolidated financial statements include the accounts of ADMA Biologics, Inc. and its wholly-owned subsidiaries.  All significant intercompany transactions and balances have been eliminated in consolidation.
Cash and cash equivalents	The Company considers all highly-liquid instruments purchased with a maturity of three months or less to be cash equivalents.  The Company purchases certificates of deposits with maturity schedules of three, six, nine and twelve months.  Instruments with original maturities greater than three months but less than twelve months are included in short-term investments.
	The Company regularly maintains cash and short-term investments at third-party financial institutions in excess of the Federal Deposit Insurance Corporation, or FDIC, insurance limit. While the Company monitors the daily cash balances in the operating accounts and adjusts the balances as appropriate, these balances could be impacted, and there could be a material adverse effect on our business, if one or more of the financial institutions with which the Company has deposits fails or is subject to other adverse conditions in the financial or credit markets. To date, the Company has not experienced a loss or lack of access to its invested cash or cash equivalents; however, the Company cannot provide assurance that access to its invested cash and cash equivalents will not be impacted by adverse conditions in the financial and credit markets.
Inventories	Plasma inventories (both plasma intended for resale and plasma intended for internal use in our research and development activities) are carried at the lower of cost or market value determined on the first-in, first-out method.    Once the research and development plasma is processed to a finished good it is then expensed to research and development for its clinical study programs.  Finished good RSV and normal source plasma is also capitalized to inventory for its potential commercialization and would subsequently be sold upon the Company receiving approval from the FDA.  Inventory at December 31, 2014 and 2013 consists of finished good RSV and normal source plasma.  Inventory also includes plasma collected at the Company’s FDA licensed plasma collection center
Revenue recognition	Revenue from the sale of human plasma collected at the Company’s FDA licensed plasma collection center and plasma-derived medicinal products is recognized at the time of transfer of title and risk of loss to the customer, which occurs at the time of shipment.  Revenue is recognized at the time of delivery if the Company retains the risk of loss during shipment.  The Company’s revenues are substantially attributed to one customer.  Revenue from license fees and research and development services rendered are recognized as revenue when the performance obligations under the terms of the license agreement have been completed.  Deferred revenue of $1.7 million was recorded in 2013 as a result of certain research and development services to be provided in accordance with a license agreement and is recognized over the term of the license.  Deferred revenue is amortized into income for a period of approximately 20 years, the term of the license agreement.
Concentration of significant customers and accounts receivable	As of and for the years ended December 31, 2014 and 2013, the Company’s trade receivable balance and revenues were substantially attributable to one customer.
Research and development costs	The Company expenses all research and development costs as incurred including plasma and equipment for which there is no alternative future use.  Such expenses include licensing fees and costs associated with planning and conducting clinical trials.
Use of estimates	The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Actual results could differ from those estimates.  Significant estimates include valuation of inventory, assumptions used in the fair value of stock-based compensation and warrant valuation, and the allowance for the valuation of future tax benefits.
Concentration of credit risk	Financial instruments which potentially subject the Company to concentrations of credit risk consist of cash and cash equivalents and short-term investments.
Property and equipment	Fixed assets are stated at cost less accumulated depreciation.  Depreciation is calculated using the straight-line method over the asset’s estimated useful life, which is five to ten years.  Leasehold improvements are amortized over the lesser of the lease term or their estimated useful lives.
Income taxes	The Company recognizes deferred tax liabilities and assets for the expected future tax consequences of events that have been included in the financial statements or tax returns.  Under this method, deferred tax liabilities and assets are determined on the basis of the difference between the tax basis of assets and liabilities and their respective financial reporting amounts (“temporary differences”) at enacted tax rates in effect for the years in which the temporary differences are expected to reverse.  The Company records a valuation allowance on its deferred income tax assets if it is more likely than not that these deferred income tax assets will not be realized.
	The Company has no unrecognized tax benefits at December 31, 2014 and 2013.  The Company’s U.S. Federal and state income tax returns prior to fiscal year 2011 are closed and management continually evaluates expiring statutes of limitations, audits, proposed settlements, changes in tax law and new authoritative rulings.
	The Company will recognize interest and penalties associated with tax matters as income tax expense.
Earnings (Loss) Per Share	Basic net loss per share is computed by dividing net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding during the period.  Diluted net loss per share is calculated by dividing net loss applicable to common stockholders as adjusted for the effect of dilutive securities, if any, by the weighted average number of common stock and dilutive common stock outstanding during the period.  No potentially dilutive securities are included in the computation of any diluted per share amounts as the Company reported a net loss for all periods presented.  Potentially dilutive securities that would be issued upon the exercise of outstanding warrants and stock options were 1.3 million at December 31, 2014 and 1.0 million at December 31, 2013.
Stock-based compensation	The Company follows recognized accounting guidance which requires all stock-based payments, including grants of stock options, to be recognized in the statement of operations as compensation expense, based on their fair values on the grant date.  The estimated fair value of options granted under the Company’s 2007 Employee Stock Option Plan (the “Plan”) are recognized as compensation expense over the option-service period.
	On June 19, 2014, at the Annual Meeting of Stockholders (the “Annual Meeting”), the stockholders approved the 2014 Omnibus Incentive Compensation Plan (the “2014 Plan”), which was approved by the Board of Directors of ADMA (“the Board”) on February 21, 2014.  Grants of incentive stock options to purchase an aggregate of 167,932 shares of the Company's common stock under the 2014 Plan to three executive officers were approved by the Board on February 21, 2014, and conditioned upon the approval of the 2014 Plan.  These stock options are comprised of 99,309 shares for the Company’s President and Chief Executive Officer, Adam S. Grossman; 39,032 shares for the Company’s Chief Financial Officer, Brian Lenz; and 29,591 shares for the Company's Chief Scientific and Medical Officer, James Mond, M.D., Ph.D.  The stock options vest over a period of four years and are exercisable at a price per share of $8.50, the closing price of the Company’s common stock on the OTC Bulletin Board on February 21, 2014.  Grants of non-qualified stock options to purchase 9,000 shares of the Company's common stock under the 2014 Plan, to each of the Company’s six non-employee directors, were approved by the Board on February 21, 2014, and were also conditioned upon the approval of the 2014 Plan at the 2014 Annual Meeting of Stockholders.  The stock options will vest over a period of 24 months and terminate 12 months following separation and are exercisable at a price per share of $8.50, the closing price of the Company’s common stock on the OTC Bulletin Board on February 21, 2014. The maximum number of shares reserved for grant under the 2014 Plan is: (a) 800,000 shares; plus (b) an annual increase as of the first day of the Company’s fiscal year, beginning in 2015 and occurring each year thereafter through 2020, equal to the least of (i) 200,000 shares, (ii) 1% of the outstanding shares of common stock as of the end of the Company’s immediately preceding fiscal year, and (iii) any lesser number of shares determined by the Board; provided, however, that the aggregate number of shares available for issuance pursuant to such increases shall not exceed a total of 800,000 shares.  During the years ended December 31, 2014 and 2013, stock options to purchase 221,932 and 84,134 shares of common stock, respectively, were issued to employees and non-employee directors.
	During the years ended December 31, 2014 and 2013, the Company recorded stock-based compensation expense to employees of $1,248,454 and $888,295, respectively.  The fair value of employee options granted was determined on the date of grant using the Black-Scholes model.  The Black-Scholes option valuation model was developed for use in estimating the fair value of publicly traded options, which have no vesting restrictions and are fully transferable.  In addition, option valuation models require the input of highly subjective assumptions including the expected stock price volatility.  The Company’s employee stock options have characteristics significantly different from those of traded options, and changes in the subjective input assumptions can materially affect the fair value estimate.  Because the Company has had very little historical experience with the Company’s stock options, small similar publicly traded companies were used for comparison and expectations as to assumptions required for fair value computation using the Black-Scholes methodology.  Guidance for stock-based compensation requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.  The Company currently estimates there will be no forfeitures of options.  Due to the Company’s limited history and as permitted under recognized guidance, the Company uses the simplified method, to determine the expected life of the option grants, which is the average between vesting terms and contractual terms.
	The Company records compensation expense associated with stock options and other forms of equity compensation using the Black-Scholes option-pricing model and the following assumptions:
		Year Ended	Year Ended
		31-Dec-14	31-Dec-13
	Expected term	6.3 years	6.3 years
	Volatility	60%	63%
	Dividend yield	0	0
	Risk-free interest rate	2.19%	1.24-2.25%
Fair value of financial instruments	The carrying amounts of certain of the Company’s financial instruments, including cash and cash equivalents, short-term investments, accounts payable, and notes payable are shown at cost which approximates fair value due to the short-term nature of these instruments.

2_SUMMARY_OF_SIGNIFICANT_ACCOU2

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Schedule of assumptions used for equity compensation expense		Year Ended	Year Ended
		31-Dec-14	31-Dec-13
	Expected term	6.3 years	6.3 years
	Volatility	60%	63%
	Dividend yield	0	0
	Risk-free interest rate	2.19%	1.24-2.25%

3_PROPERTY_AND_EQUIPMENT_Table

3. PROPERTY AND EQUIPMENT (Tables)	12 Months Ended
	Dec. 31, 2014
Property And Equipment Tables
Schedule of property and equipment	Property and equipment consist of the following at December 31,	2014		2013
	Lab and office equipment	$	1,236,553	$	674,885
	Computer software		188,277		184,077
	Leasehold improvements		2,699,736		942,353
			4,124,566		1,801,315
	Less: Accumulated depreciation and amortization		-1,283,868		-1,036,016
		$	2,840,698	$	765,299

4_LEASEHOLD_IMPROVEMENT_LOAN_T

4. LEASEHOLD IMPROVEMENT LOAN (Tables)	12 Months Ended
	Dec. 31, 2014
Notes to Financial Statements
Schedule Principal maturities under leasehold improvement loan	2015	$	13,841
	2016		15,139
	2017		16,559
	2018		18,113
	2019		1,584
		$	65,236

8_COMMITMENTS_AND_CONTINGENCIE1

8. COMMITMENTS AND CONTINGENCIES (Tables)	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Future minimum lease payments	2015	$	330,176
	2016		348,383
	2017		353,059
	2018		356,774
	2019		369,198
	Thereafter		1,465,720
		$	3,223,310

9_STOCK_OPTIONS_Tables

9. STOCK OPTIONS (Tables)	12 Months Ended
	Dec. 31, 2014
Equity [Abstract]
Schedule of stock options outstanding		Year Ended				Year Ended
		31-Dec-14				31-Dec-13
				Weighted				Weighted
				Average				Average
				Exercise				Exercise
		Shares		Price		Shares		Price
	Outstanding at beginning of year		826,995	$	6.9		749,211	$	6.86
	Forfeited		-		-		-6,350	$	7.56
	Granted		221,932	$	8.5		84,134	$	7.56
	Outstanding at end of year and expected to vest		1,048,927	$	7.24		826,995	$	6.9
	Options exercisable		635,763	$	6.81		391,822	$	6.23
	Weighted average fair value of options
	granted during the year			$	5.06			$	4.35
Stock-based compensation expense		2014		2013
	Research and development	$	541,140	$	227,085
	Plasma centers		56,900		-
	General and administrative		650,414		661,210
	Total stock-based compensation expense	$	1,248,454	$	888,295

10_INCOME_TAXES_Tables

10. INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Schedule of reconciliation of income taxes		Year Ended December 31,
		2014		2013
	Benefit at US Federal statutory rate	$	-5,904,062	$	-5,279,264
	State taxes - deferred		879,793		-901,800
	Increase in valuation allowance		5,147,244		6,850,118
	Research and development credits		-551,863		-599,003
	Sale of state net operating loss		-551,724		-
	Other		428,888		-70,051
	Benefit for income taxes	$	-551,724	$	-
Schedule of deferred tax asset		Year Ended December 31,
		2014		2013
	Federal and state net operating loss carryforwards	$	21,004,587	$	16,791,893
	Federal and state research credits		3,649,268		2,846,245
	Accrued expenses and other		884,472		752,945
	Total gross deferred tax assets		25,538,327		20,391,083
	Less: valuation allowance for deferred tax assets		-25,538,327		-20,391,083
	Net deferred tax assets	$	-	$	-

11_SEGMENTS_Tables

11. SEGMENTS (Tables)	12 Months Ended
	Dec. 31, 2014
Segment Reporting [Abstract]
SEGMENTS
	Year Ended December 31,	Plasma Collection			Research and
	2014	Center			Development			Corporate			Consolidated
	Revenues	$	5,839,989		$	-		$	75,556		$	5,915,545
	Cost of product revenue		3,742,367			-			-			3,742,367
	Gross profit		2,097,622			-			75,556			2,173,178
	Loss from operations		(1,753,206	)		(9,517,014	)		(4,748,313	)		(16,018,533	)
	Other income (expense)		262			-			(1,346,616	)		(1,346,354	)
	Loss before income taxes		(1,752,944	)		(9,517,014	)		(6,094,929	)		(17,364,887	)
	Property and equipment, net		2,697,390			-			143,308			2,840,698
	Depreciation and
	amortization expense		198,244			2,729			46,879			247,852
	Year Ended December 31,	Plasma Collection			Research and
	2013	Center			Development			Corporate			Consolidated
	Revenues	$	3,023,503		$	-		$	44,074		$	3,067,577
	Cost of product revenue		2,023,441			-			-			2,023,441
	Gross profit		1,000,062			-			44,074			1,044,136
	Loss from operations		(1,418,094	)		(9,303,077	)		(4,321,260	)		(15,042,431	)
	Other expense		(7,582	)		-			(477,233	)		(484,815	)
	Loss before income taxes		(1,425,676	)		(9,303,077	)		(4,798,493	)		(15,527,246	)
	Property and equipment, net		587,032			2,729			175,538			765,299
	Depreciation and
	amortization expense		168,686			3,238			38,709			210,633

1_ORGANIZATION_AND_BUSINESS_De

1. ORGANIZATION AND BUSINESS (Details Narrative) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Accounting Policies [Abstract]
Cash and cash equivalents	$17,199,030	$26,149,477	$12,535,672
Short-term investments	4,652,675	2,935,184
Accounts receivable	$383,961	$0

2_SUMMARY_OF_SIGNIFICANT_ACCOU3

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Summary Of Significant Accounting Policies Details
Expected term	6 years 3 months 18 days	6 years 3 months 18 days
Volatility	60.00%	63.00%
Dividend yield	0.00%	0.00%
Risk-free interest rate Minimum		1.24%
Risk-free interest rate Maximum		2.25%
Risk-free interest rate	2.19%

2_SUMMARY_OF_SIGNIFICANT_ACCOU4

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Summary Of Significant Accounting Policies Details Narrative
Options issued to employees and non-employee directors	221,932	84,134
Stock-based compensation	$1,248,454	$888,295

3_PROPERTY_AND_EQUIPMENT_Detai

3. PROPERTY AND EQUIPMENT (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Property And Equipment Tables
Lab and office equipment	$1,236,553	$674,885
Computer software	188,277	184,077
Leasehold improvements	2,699,736	942,353
Total gross	4,124,566	1,801,315
Less: Accumulated depreciation and amortization	-1,283,868	-1,036,016
Net	$2,840,698	$765,299

3_PROPERTY_AND_EQUIPMENT_Detai1

3. PROPERTY AND EQUIPMENT (Details Narrative) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Abstract]
Depreciation and amortization expense	$247,852	$210,633

4_LEASEHOLD_IMPROVEMENT_LOAN_D

4. LEASEHOLD IMPROVEMENT LOAN (Details) (USD $)	Dec. 31, 2014
Notes to Financial Statements
2015	$13,841
2016	15,139
2017	16,559
2018	18,113
2019	1,584
Total	$65,236

5_DEBT_Details_Narrative

5. DEBT (Details Narrative) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Debt Disclosure [Abstract]
Warrants purchase share of common stock, value	$476,760	$0
Warrants purchase share of common stock, shares	58,000	31,750
Change in fair value of warrants liability	$74,356	($43,290)

6_STOCKHOLDERS_EQUITY_Details_

6. STOCKHOLDERS EQUITY (Details Narrative) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Stockholders Equity Details Narrative
Warrants issued	58,000	31,750
Exercise price	$7.50	$7.56

7_RELATED_PARTY_TRANSACTIONS_D

7. RELATED PARTY TRANSACTIONS (Details Narrative) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Related Party Transactions [Abstract]
Rent expense	$96,448	$96,448

8_COMMITMENTS_AND_CONTINGENCIE2

8. COMMITMENTS AND CONTINGENCIES (Details) (USD $)	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
2015	$330,176
2016	348,383
2017	353,059
2018	356,774
2019	369,198
Thereafter	1,465,720
Total	$3,223,310

8_COMMITMENTS_AND_CONTINGENCIE3

8. COMMITMENTS AND CONTINGENCIES (Details Narrative) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]
Rent expenses	$414,000	$253,000

9_STOCK_OPTIONS_Details

9. STOCK OPTIONS (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Shares
Outstanding at beginning of year	826,995	749,211
Forfeited	0	-6,350
Granted	221,932	84,134
Outstanding at end of year and expected to vest	1,048,927	826,995
Options exercisable	635,763	391,822
Weighted Average Exercise Price
Outstanding at beginning of year	$6.90	$6.86
Forfeited	$0	$7.56
Granted	$8.50	$7.56
Outstanding at end of year and expected to vest	$7.24	$6.90
Options exercisable	$6.81	$6.23
Weighted average fair value of options granted during the year	$5.06	$4.35

9_STOCK_OPTIONS_Details_1

9. STOCK OPTIONS (Details 1) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Stock-based compensation expenses
Total stock-based compensation expense	$1,248,454	$888,295
Research and Development Expense
Stock-based compensation expenses
Total stock-based compensation expense	541,140	227,085
General and Administrative Expense
Stock-based compensation expenses
Total stock-based compensation expense	56,900	0
Plasma centers [Member]
Stock-based compensation expenses
Total stock-based compensation expense	$650,414	$661,210

9_STOCK_OPTIONS_Details_Narrat

9. STOCK OPTIONS (Details Narrative) (USD $)	12 Months Ended
	Dec. 31, 2014
Equity [Abstract]
Total unrecognized compensation expense related to unvested options	$2,158,560
Total unrecognized compensation expense related to unvested options, period	2 years 1 month 6 days
Options available for future grant	654,297
Option Outstanding intrinsic value	4,121,481
Exercisable options intrinsic value	$2,771,874

10_INCOME_TAXES_Details

10. INCOME TAXES (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Income Tax Disclosure [Abstract]
Benefit at US federal statutory rate	($5,904,062)	($5,279,264)
State taxes - deferred	879,793	-901,800
Increase in valuation allowance	5,147,244	6,850,118
Research and development credits	-551,863	-599,003
Sale of state net operating loss	-551,724	0
Other	428,888	-70,051
Benefit for income taxes	($551,724)	$0

10_INCOME_TAXES_Details_1

10. INCOME TAXES (Details 1) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Deferred tax assets:
Federal and state net operating loss carryforwards	$21,004,587	$16,791,893
Federal and state research credits	3,649,268	2,846,245
Accrued expenses and other	884,472	752,945
Total gross deferred tax assets	25,538,327	20,391,083
Less: valuation allowance for deferred tax assets	-25,538,327	-20,391,083
Net deferred tax assets	$0	$0

10_INCOME_TAXES_Details_Narrat

10. INCOME TAXES (Details Narrative) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Income Tax Disclosure [Abstract]
Federal and state net operating loss carryforwards	$58,900,000	$31,900,000
Federal and state research and development tax credit carryforwards	$3,000,000	$600,000

11_SEGMENTS_Details

11. SEGMENTS (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Summarized financial information concerning reportable segments
Revenues	$5,915,545	$3,067,577
Cost of product revenue	3,742,367	2,023,441
Gross profit	2,173,178	1,044,136
Loss from operations	-16,018,533	-15,042,431
Other income (expense)	-1,346,354	-484,815
Loss before income taxes	-17,364,887	-15,527,246
Property and equipment, net	2,840,698	765,299
Depreciation and amortization expense	247,852	210,633
Plasma Collection Center [Member]
Summarized financial information concerning reportable segments
Revenues	5,839,989	3,023,503
Cost of product revenue	3,742,367	2,023,441
Gross profit	2,097,622	1,000,062
Loss from operations	-1,753,206	-1,418,094
Other income (expense)	262	-7,582
Loss before income taxes	-1,752,944	-1,425,676
Property and equipment, net	2,697,390	587,032
Depreciation and amortization expense	198,244	168,686
Research And Development [Member]
Summarized financial information concerning reportable segments
Revenues	0	0
Cost of product revenue	0	0
Gross profit	0	0
Loss from operations	-9,517,014	-9,303,077
Other income (expense)	0	0
Loss before income taxes	-9,517,014	-9,303,077
Property and equipment, net	0	2,729
Depreciation and amortization expense	2,729	3,238
Corporate [Member]
Summarized financial information concerning reportable segments
Revenues	75,556	44,074
Cost of product revenue	0	0
Gross profit	75,556	44,074
Loss from operations	-4,748,313	-4,321,260
Other income (expense)	-1,346,616	-477,233
Loss before income taxes	-6,094,929	-4,798,493
Property and equipment, net	143,308	175,538
Depreciation and amortization expense	$46,879	$38,709